Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naporafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 19/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 14/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | ARAF | P10398 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naporafenib SCHEMBL29411709 | 1.00 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| Naporafenib SCHEMBL30241122 | 1.00 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| Naporafenib SCHEMBL16094629 | 1.00 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL16100633 | 0.95 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL16101260 | 0.95 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL16121843 | 0.93 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL17583455 | 0.92 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL17523511 | 0.92 | RAF1 (0.85) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL16121752 | 0.91 | RAF1 (1.00) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL17523483 | 0.91 | RAF1 (0.84) | RAF1BRAFPDGFRBARAFDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1083 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | claimed |
| US-20250312334-A1 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF RAF INHIBITOR | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2025-10-09 | — | — | US | claimed |
| EP-3957631-B1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2025-09-10 | — | — | EP | claimed |
| EP-4611748-A1 | COMBINATION THERAPY FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4587026-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2025-07-23 | — | — | EP | claimed |
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| CN-114258318-A | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-29 | — | — | CN | claimed |
| EP-3966206-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3966207-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| CN-114127057-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220054492-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| CN-114072397-A | Heteroaryl aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | RAF1 1860/4885BRAF 408/4885PDGFRB 339/4885 |
| US-20220054492-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | RAF1 5/4885BRAF 4/4885PDGFRB 789/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | RAF1 50/4885BRAF 1/4885PDGFRB 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.